BioSpace News Archive

Cytokinetics, Inc. (Nasdaq: CYTK) today announced that the first patient has been dosed in Cohort 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of CK-3773274 (CK-274)

Preliminary total pro-forma combined revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.3 million cash as of December 31, 2020 and total capital raised in 2020 of $35.3 million OpGen subsidiary Ares Genetics to explore multiple collaboration opportunities with several parties

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced plans to begin enrolling the Sentinel Trial in the first half of 2021.

LumiraDx, the next generation point-of-care diagnostic company, announced that the Scandinavian evaluation of laboratory equipment for point of care testing had published a positive evaluation of the LumiraDx SARS-CoV-2 Antigen Test.

Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, announced the appointment of Ross Wheatcroft as the Global Strategic Accounts Manager.

EVOQ Therapeutics announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders.

CT-P59 (40mg/kg) treated patients reported reduced progression rates to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over

The extraordinary general meeting in Medivir Aktiebolag on 13 January 2021 resolved, in accordance with the board of directors’ proposal, to decrease the company’s share capital with SEK 20,908,234.356976 without cancellation of shares.

Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it co-sponsored the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatmen

Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021.